Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APT NASDAQ:BDMD NASDAQ:PSTV NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$4.93+6.6%$4.76$4.25▼$5.64$50.16M0.835,856 shs29,585 shsBDMDBaird Medical Investment$1.81-0.5%$2.09$0.76▼$7.26$74.17M-1.181.57 million shs88,978 shsPSTVPlus Therapeutics$5.95-4.3%$6.09$2.90▼$23.42$40.84M1.4429,703 shs120,952 shsVVOSVivos Therapeutics$0.73+3.5%$1.21$0.69▼$7.95$9.99M6.25195,616 shs102,571 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech+0.43%+1.54%+4.05%-10.64%+4.05%BDMDBaird Medical Investment+1.68%+8.33%-6.67%+85.22%-66.67%PSTVPlus Therapeutics+2.13%+4.54%+74.72%+2.77%-59.89%VVOSVivos Therapeutics-12.10%-16.47%-46.25%-52.70%-72.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$4.93+6.6%$4.76$4.25▼$5.64$50.16M0.835,856 shs29,585 shsBDMDBaird Medical Investment$1.81-0.5%$2.09$0.76▼$7.26$74.17M-1.181.57 million shs88,978 shsPSTVPlus Therapeutics$5.95-4.3%$6.09$2.90▼$23.42$40.84M1.4429,703 shs120,952 shsVVOSVivos Therapeutics$0.73+3.5%$1.21$0.69▼$7.95$9.99M6.25195,616 shs102,571 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech+0.43%+1.54%+4.05%-10.64%+4.05%BDMDBaird Medical Investment+1.68%+8.33%-6.67%+85.22%-66.67%PSTVPlus Therapeutics+2.13%+4.54%+74.72%+2.77%-59.89%VVOSVivos Therapeutics-12.10%-16.47%-46.25%-52.70%-72.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTAlpha Pro Tech 0.00N/AN/AN/ABDMDBaird Medical Investment 1.00SellN/AN/APSTVPlus Therapeutics 2.43Hold$58.00865.06% UpsideVVOSVivos Therapeutics 2.20Hold$2.58255.83% UpsideCurrent Analyst Ratings BreakdownLatest VVOS, BDMD, APT, and PSTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026BDMDBaird Medical Investment Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/22/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.004/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026VVOSVivos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026VVOSVivos Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $2.504/9/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$475.00 ➝ $65.003/31/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/19/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTAlpha Pro Tech$59.14M0.85$0.38 per share12.80$5.29 per share0.93BDMDBaird Medical Investment$22.54M3.26N/AN/AN/A∞PSTVPlus Therapeutics$5.21M7.91N/AN/A$0.72 per share8.35VVOSVivos Therapeutics$17.44M0.57N/AN/A($0.16) per share-4.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTAlpha Pro Tech$4.19M$0.3413.17N/AN/A6.99%6.70%5.76%N/ABDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics-$22.39M-$31.00N/AN/AN/A-429.43%N/A-92.28%5/29/2026 (Estimated)VVOSVivos Therapeutics-$21.17M-$2.07N/AN/AN/A-121.37%-849.22%-96.11%5/21/2026 (Estimated)Latest VVOS, BDMD, APT, and PSTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026PSTVPlus Therapeutics-$0.8460N/AN/AN/A$0.97 millionN/A5/21/2026Q1 2026VVOSVivos Therapeutics-$0.45N/AN/AN/A$4.35 millionN/A4/15/2026Q4 2025VVOSVivos Therapeutics-$0.4950-$0.58-$0.0850-$0.58$7.10 million$3.82 million3/12/2026Q4 2025PSTVPlus Therapeutics-$0.03$6.25+$6.28N/A$1.23 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPTAlpha Pro TechN/AN/AN/AN/AN/ABDMDBaird Medical InvestmentN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTAlpha Pro TechN/A19.0011.21BDMDBaird Medical InvestmentN/AN/AN/APSTVPlus TherapeuticsN/A1.231.23VVOSVivos Therapeutics3.310.240.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTAlpha Pro Tech22.69%BDMDBaird Medical Investment19.78%PSTVPlus Therapeutics3.28%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipAPTAlpha Pro Tech15.00%BDMDBaird Medical Investment78.90%PSTVPlus Therapeutics2.50%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTAlpha Pro Tech12010.19 million9.46 millionOptionableBDMDBaird Medical InvestmentN/A40.98 million8.65 millionN/APSTVPlus Therapeutics206.86 million6.69 millionNot OptionableVVOSVivos Therapeutics16013.61 million13.33 millionOptionableVVOS, BDMD, APT, and PSTV HeadlinesRecent News About These CompaniesVivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47April 29, 2026 | msn.comVivos Therapeutics Faces Nasdaq Listing Compliance ChallengesApril 22, 2026 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call TranscriptApril 17, 2026 | insidermonkey.comVivos Therapeutics Q4 Earnings Call HighlightsApril 17, 2026 | defenseworld.netDVivos Therapeutics Balances Growth Hopes With Cash StrainApril 16, 2026 | tipranks.comVivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potentialApril 16, 2026 | seekingalpha.comVivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ...April 16, 2026 | finance.yahoo.comVivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call TranscriptApril 15, 2026 | seekingalpha.comVivos Therapeutics Reports Full Year 2025 Financial ResultsApril 15, 2026 | globenewswire.comVivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026April 15, 2026 | quiverquant.comQVivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference CallApril 15, 2026 | globenewswire.comVivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca PartnersApril 7, 2026 | globenewswire.comVivos Therapeutics Completes Private Placement to Bolster LiquidityApril 3, 2026 | tipranks.comInsider Buying: Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Buys 1,353,625 Shares of StockApril 3, 2026 | insidertrades.comVivos Therapeutics investor V-Co investors 3 LLC buys shares worth $1.8mApril 2, 2026 | investing.comVivos Therapeutics secures Nevada insurer access and implements cost cutsMarch 26, 2026 | msn.comVivos Therapeutics Announces In-Network Insurance Coverage for OSA Treatments in Nevada and Initiates Cost Reduction MeasuresMarch 26, 2026 | quiverquant.comQVivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada MarketMarch 26, 2026 | globenewswire.comVivos Therapeutics, Inc. Study Affirms Link Between Dental Morphology and Obstructive Sleep Apnea SeverityMarch 17, 2026 | quiverquant.comQRecent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral AnatomyMarch 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026The $100 Barrel Is Back: Trading The Hormuz Havoc By Jeffrey Neal Johnson | April 15, 2026VVOS, BDMD, APT, and PSTV Company DescriptionsAlpha Pro Tech NYSE:APT$4.92 +0.31 (+6.60%) As of 01:10 PM Eastern This is a fair market value price provided by Massive. Learn more.Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.Baird Medical Investment NASDAQ:BDMD$1.81 -0.01 (-0.55%) As of 01:11 PM Eastern This is a fair market value price provided by Massive. Learn more.Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.Plus Therapeutics NASDAQ:PSTV$5.95 -0.27 (-4.29%) As of 01:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Vivos Therapeutics NASDAQ:VVOS$0.73 +0.02 (+3.45%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
